HLA-A24 binding cancer antigen peptide derived from livin

Details HLA-A24 binding cancer antigen peptide derived from livin HLA-A24 binding cancer antigen peptide derived from livin

2004-07-07

2009-10-13

Huff, Sheela J (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

8 to 10 amino acid residues in defined sequence

C530S327000

Reexamination Certificate

active

07601801

ABSTRACT:
The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.

REFERENCES:
patent: 2003/0087319 (2003-05-01), Gomes et al.
patent: 2003/0157522 (2003-08-01), Boudreault et al.
patent: 2007/0036811 (2007-02-01), Straten et al.
patent: 2002-284797 (2002-10-01), None
patent: 2002-316998 (2002-10-01), None
patent: WO 00/77201 (2000-12-01), None
patent: WO 03/040172 (2003-05-01), None
patent: WO 2004/089980 (2004-10-01), None
Schmollinger et al PNAS vol. 100 p. 3398 (2003).
Essell (J. NIH Res. 1995 7:46).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv. Can. Res. 1992 58:177-210).
Lee et al, J. Immunology vol. 163 p. 6296 (1999).
Balch et al., Arch. Surg. vol. 125, pp. 200-205, (1990).
Anichini et al., Immunology Today, vol. 8, No. 12, pp. 385-389,(1987).
Muul et al., The Journal of Immunology, vol. 138, No. 3, pp. 989-995, (1987).
Ioth et al., Int. J. Cancer, vol. 52, pp. 52-59 (1992).
Rosenberg et al., Journal of the National Cancer Institute, vol. 86, No. 15, pp. 1159-1166 (1994).
Van Der Bruggen et a., Science, vol. 254, pp. 1643-1647, (1991).
Boon et al., Immunology Today, vol. 18, No. 6, pp. 267,268, (1997).
Boon et al., J. Exp. Med. vol. 183, pp. 725-729 (1996).
Robbins et al., Curr. Opin. Immunol., vol. 8 pp. 628-636 (1996).
Vucic et al., Curr. Biol., vol. 10., No. 21, pp. 1359-1366 (2000).
NCBI database Accession NO AAG33622, pp. 9.
Rammensee et al., Immunogenetics, vol. 41, pp. 178-228 (1995).
Kondo et al., J. Immunology, vol. 155, pp. 4307-4312 (1995).
Kubo et al., J. Immunol. vol. 152, pp. 3913-3924, (1994).
Kast et al., J. Immunol. vol. 152, pp. 3904-3912, (1994).
Schmollinger JC. et al., Natl. Acad. Sci. USA., Mar. 18, 2003, vol. 100, No. 6, pp. 3398 to 3403.
Kasof GM. et al., J. Biol. Chem. (2001), vol. 276, No. 5, pp. 3238 to 3246.

Affiliated with

Also associated with

Rating

HLA-A24 binding cancer antigen peptide derived from livin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HLA-A24 binding cancer antigen peptide derived from livin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-A24 binding cancer antigen peptide derived from livin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4130016